1. LUMINEX
CORPORATION
First Quarter 2011
Results of Operations
May 9, 2011
Patrick J. Balthrop, President and Chief Executive Officer
Harriss T. Currie, Vice President and Chief Financial Officer
1 Leading. Innovating. Growing.
2. Safe Harbor
Certain statements made during the course of this presentation may not be purely historical and consequently may
be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
but not limited to: statements made regarding our partners’ commitment to, expansion of, and end-customer
demand for our technology; long-term demand for and quarterly variability in bulk orders of consumables; volatility
in consumables revenue and distribution and growth of such revenue during 2011 and beyond; the market launch
of xTAG GPP, its technical capabilities, and the anticipated market size, demand and regulatory approvals therefor;
our system and assay product pipeline and anticipated timelines for regulatory approvals and market release,
including for our RVP FAST and NeoPlex 4 assays; our collaboration with Partners HealthCare and its ability to
accelerate the development and commercialization of novel assays to address unmet clinical needs; the full
commercial launch of our MAGPIX instrument, including expected market demand and future distribution therefor;
future R&D and SG&A expenditures, variability thereof, and long-term targets therefor; our commitment to deliver
revenue growth and manage operating costs; the strength of our balance sheet and sustainable levels of days
sales outstanding; the markets we and our partners are targeting and their expected growth; our partnership model
and the ability of our partners and our installed base to drive future growth in demand for our technology; the
ability of our technology to enhance productivity and efficiency; our strategic outlook and growth plan for our
business for 2011 and beyond; our long term financial targets; operational trends, including those related to sales
of consumables, royalty revenues and inventory levels; our business outlook and projections about revenues, cash
flow, system shipments, expenses and market conditions, and their anticipated impact on Luminex; information
regarding development, timing and performance of new products; and, any statements of the plans, strategies and
objectives of management for future operations. These forward looking statements speak only as of the date hereof
and are based on our current beliefs and expectations and are subject to known or unknown risks and
uncertainties some of which are beyond the company’s control that could cause actual results or plans to differ
materially and adversely from those anticipated in the forward looking statements. Factors that could cause or
contribute to such differences are detailed in our press release or in our annual, quarterly, or other filings with the
Securities and Exchange Commission. We undertake no obligation to update these forward looking statements.
Also, certain non-GAAP financial measures as defined by SEC Regulation G, may be covered in this presentation.
To the extent that any non-GAAP financial measures are covered, a presentation of and reconciliation to the most
directly comparable GAAP financial measures will be included in this presentation and/or be available on our
website at www.luminexcorp.com in accordance with Regulation G.
2 Leading. Innovating. Growing.
4. 1Q11 Highlights
Employees and office in Tokyo are safe; experienced minimal disruption
• Consolidated 1Q revenue of • In May, received CE Mark for
$43.3M (+30% Y/Y): our xTAG® GPP assay
• Consumables of $15.0M (+53%)
• Collaboration with Partners
• Assay sales of $9.6M (+25%) HealthCare in Boston
• Consolidated gross margin of • In April, received the Medical
71%, +250bps Y/Y Design Excellence Award for
• Operating income of 19% of MAGPIX ®
consolidated revenue • Third consecutive year on
• Net income of $4.5M, or $0.11 Forbes’ list of the 25 fastest-
per fully diluted share growing technology companies
4 Leading. Innovating. Growing.
6. xTAG® GPP Gains CE Mark
• xTAG Gastrointestinal
Pathogen Panel (GPP) CE
Mark received in May
NeoPlex4™ CE Mark RVP-FAST US IVD
• Value Proposition of GPP:
• Targets 15 pathogens
(viruses, parasites, toxins
and bacteria)
• Strong clinical results
(sensitivity/specificity)
Meningitis CE Mark
• Substantial market
opportunity ~ $150M WW
• Synergies with RVP and
Flock Monitor - USDA Fungal ASR current EU installed base
6 Leading. Innovating. Growing.
7. Collaboration with Partners HealthCare
• Partners HealthCare is a premier
integrated health system and one of
the nation's leading biomedical
research organizations "Luminex's xMAP technology provides an ideal
platform for Partners HealthCare to translate novel
biomarker discoveries into cutting-edge tests and
• Collaboration enables Partners accelerate adoption of new molecular tests to provide
HealthCare Center for Personalized the best clinical care for patients."
Genetic Medicine (PCPGM) to develop
novel molecular diagnostic assays Dr. Heidi Rehm, Director
PCPGM's Laboratory for Molecular Medicine at
based on biomarkers discovered within Partners HealthCare
Partners HealthCare entities
• These innovative molecular diagnostic
tests will operate on Luminex's
proprietary xMAP® platform
7 Leading. Innovating. Growing.
8. MAGPIX® Limited Launch Update
• Solid early uptake –
113 units to date
• Compact system offers
Price and throughput
single or multiplex (up to LX 200™
50 analytes per well)
Immunoassay Research Market Facts
capabilities
North America market: ~ $400M
Customer mix: Academia (40%)
• Protein and nucleic acid
~135,000 US researchers
applications 39% of ELISA users interested in
multiplexing in next 12 months*
MAGPIX®
• Cost advantages over
ELISA
* Source: Biocompare Immunoassays 2008 – An End User Survey
• Initial target market:
Immunoassay research Potential Installations
8 Leading. Innovating. Growing.
11. 1Q11 Segment Results
($ in thousands - except per share amounts)
1Q 2011 1Q 2010 Variance
Revenue
Technology & Strategic Partnerships $ 31,935 $ 25,216 $ 6,719
Assays & Related Products 11,340 8,036 3,304
Total Revenue 43,275 33,252 10,023
Operating Income (Loss)
Technology & Strategic Partnerships 8,656 4,296 4,360
Assays & Related Products (362) (548) 186
Total Operating Income $ 8,294 $ 3,748 $ 4,546
Total Operating Margin 19% 11% 8%
11 Leading. Innovating. Growing.
12. 1Q11 Revenue Distribution
(1) (2)
Segment Sales Growth % of Sales Highlights
Systems $7.7 15% 18% 197 multiplexing analyzers, includes 38 MAGPIX
Consumables $15.0 53% 35% 19 bulk orders total $13.3M range: $105K - $9M
Royalties $7.3 24% 17% Overall adoption of xMAP; 1Q minimum payments
Assays $9.6 25% 22% CF and RVP Franchises ~ 88% of assay revenue
Other $3.8 16% 8% Service and maintenance on growing installed base
Footnotes:
(1) Dollars in millions
(2)Year-over-year
12 Leading. Innovating. Growing.
13. Potential for Operating Leverage
Research and Development ($M) Sales, General and Administrative
($ in millions) (% of Total Revenue)
17.5% 16.5% of Rev
• Focus on driving growth • Continued focus on
through significant operating leverage,
continued investment in R&D particularly in G&A
13 Leading. Innovating. Growing.
15. Cash & Investment Flow
($ in millions)
+ 11.2
- 1.2
- 2.0 + 0.5 129.2
- 3.3
123.9
Footnotes:
(1) OCF excludes the excess income tax benefit from employee stock-based awards
15 Leading. Innovating. Growing.
16. 2011 Guidance Reiterated
• 2011 revenue guidance of $163-$170M
• Reiteration of 2011 guidance based on our expectation:
• 1H11 consumable sales (in $) likely to be greater than 2H11
• Limited contribution from new assays (e.g. qBead, GPP, CYP2D6)
• Normal-to-light Influenza-Like-Illness (ILI) season
16 Leading. Innovating. Growing.
17. Long Term Financial Targets
• Long-term Compounded Annual Revenue Growth of 20+ Percent
• All Metrics Except Revenue Growth Expressed in Percent of Annual Revenue
Long Term
Metric 2007 2008 2009 2010 1Q11 Targets
Revenue 100% 100% 100% 100% 100%
Revenue Growth (YoY) 42% 39% 16% 17% 30% 20+%
Gross Profit 61% 68% 67% 68% 71% 65% - 75%
R&D Expense 21% 18% 17% 17% 18% 15%
Pretax Income (Loss) (3)% 4% 6%* 8% 19% 25% - 35%
*Adjusted for the settlement of litigation
17 Leading. Innovating. Growing.
18. 2011 Starting Out Strong…
Near-Term Catalysts
Additional MAGPIX distribution,
Investor event (July 25) at AACC
Strong Financial Position
Record 1Q revenue; +30% Y/Y
Cash on the balance sheet of $129.2M
Robust Product Pipeline
GPP CE Mark (Rec’d), RVP Fast in 2011, NeoPlex4 CE Mark at YE11
Leveraging Partners to Drive Adoption
Strong 1Q consumable revenue growth (+53%) driven by our top partners
18 Leading. Innovating. Growing.
